Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dose-dense chemotherapy
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
18751424
Knihovny.cz E-resources
- MeSH
- Chemotherapy, Adjuvant MeSH
- Cyclophosphamide administration & dosage MeSH
- Adult MeSH
- Doxorubicin administration & dosage MeSH
- Ferritins blood MeSH
- Hemoglobins metabolism MeSH
- Blood Cell Count MeSH
- Middle Aged MeSH
- Humans MeSH
- Breast Neoplasms, Male blood drug therapy urine MeSH
- Breast Neoplasms blood drug therapy metabolism urine MeSH
- Neoadjuvant Therapy MeSH
- Neopterin urine MeSH
- Paclitaxel administration & dosage MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Aged MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cyclophosphamide MeSH
- Doxorubicin MeSH
- Ferritins MeSH
- Hemoglobins MeSH
- Neopterin MeSH
- Paclitaxel MeSH
BACKGROUND: Among other actions, chemotherapy may induce an activation of systemic inflammatory and immune response. PATIENTS AND METHODS: Urinary neopterin was evaluated, using high-performance liquid chromatography, before and during dose-dense combination chemotherapy with doxorubicin, cyclophosphamide and sequential paclitaxel (neoadjuvant or adjuvant) in 194 patients with breast carcinoma. Hemoglobin, peripheral blood cell count and, in a subgroup of patients, iron metabolism were also evaluated. RESULTS: Urinary neopterin increased significantly during the chemotherapy. The increase in urinary neopterin was accompanied by a gradual decrease of hemoglobin. A marked increase in serum ferritin concentration was observed during the chemotherapy, along with fluctuations of iron concentrations. Among 161 patients treated with primary chemotherapy, the pathological response was evaluable in 150. Pathological complete response was observed in 37 cases (25%). In patients with pathological complete response, significantly lower serum ferritin concentrations were observed. CONCLUSION: Present data demonstrate the presence of systemic immune activation, reflected in increased urinary neopterin concentrations, in breast carcinoma patients treated with dose-dense chemotherapy. Lower ferritin concentrations were predictive of pathological complete response.
Neopterin as a biomarker of immune response in cancer patients
